PDF(Pubmed)
Abstract：
Low-grade myofibroblastic sarcoma (LGMS) characterized by the increased proliferation of myofibroblasts is a rare type of malignant myofibroblastic tumor that frequently occurs in the head and neck region. Presently, there is no consensus regarding the treatment of LGMS. Here, we report a rare case of LGMS of the pharynx in a 40-year-old male admitted to our hospital. The patient underwent resection for a right metastatic lesion and parapharyngeal mass. However, he had recurrence and multiple metastases without a surgical indication. Then the patient received the treatment of anlotinib plus pembrolizumab for 4 cycles, and there was a partial response (PR) to the treatment. Due to the adverse reaction of anlotinib, the patient subsequently received monotherapy of pembrolizumab for 22 cycles and achieved a complete response (CR). As the first case report of the immunotherapy for LGMS, our study highlights that this strategy may be of great significance to the treatment of LGMS.
摘要：
以成纤维细胞增殖增加为特征的低度肌纤维母细胞肉瘤（LGMS）是一种罕见的恶性肌纤维母细胞瘤，经常发生在头颈部。目前,关于LGMS的治疗尚无共识。这里,我们报告了一例罕见的咽部LGMS病例,其中一名40岁男性入院.患者接受了右转移性病变和咽旁肿块的切除术。然而,他有复发和多发转移，没有手术指征。然后患者接受安洛替尼联合派姆单抗治疗4个周期，对治疗有部分反应（PR）。由于安洛替尼的不良反应，患者随后接受了22个周期的派博利珠单抗单药治疗,达到完全缓解(CR).作为LGMS免疫治疗的首例病例报告，我们的研究强调这一策略可能对LGMS的治疗具有重要意义.
